Why There’s Still Room For Sarilumab In RA, According To Sanofi
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III TARGET data presented at the American College of Rheumatology meeting support the novel IL-6 inhibitor’s efficacy and safety in rheumatoid arthritis, but Sanofi and partner Regeneron are under pressure to differentiate the new biologic in a crowded market.